PODD vs PPCB · P/E 34, rev $2.07B vs P/E 0.0, $3.9M cap
Insulet Corporation (PODD) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Insulet Corporation (PODD) is a medical devices company listed on NASDAQ.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported PODD revenue for 2024-12-31 was $2.07B. Net income was $418.3M. Revenue was up 22.1% from 2023-12-31 to 2024-12-31. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
PPCB does not have a complete income-statement cache yet.
PODD currently screens at market cap $9.94B and trailing P/E 33.5. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the PODD and PPCB stock pages for the full models.
Not investment advice.